<DOC>
	<DOC>NCT00911911</DOC>
	<brief_summary>The scope of the trial is to identify proteomic signatures correlated with tumor response to neo-adjuvant chemotherapy.</brief_summary>
	<brief_title>Proteomic Signature in Breast Cancer: Correlation With Tumor Response to Neo-adjuvant Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Women aged more than 18 years Histologically proven breast carcinoma Neoadjuvant chemotherapy with anthracyclines and/or taxanes No prior chemotherapy Written informed consent Metastatic disease</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Breast cancer</keyword>
	<keyword>Neo-adjuvant chemotherapy</keyword>
	<keyword>Proteomic</keyword>
	<keyword>Histological response</keyword>
</DOC>